AAOS:髋部骨折术后入住ICU升压药支持生存率较差

2014-03-27 佚名 DXY

髋部骨折病例伴有明显的合并症发生率及死亡率。但到目前为止,尚缺乏对因为出现并发症而入住ICU监护治疗的髋部骨折病例的相关研究。本研究试图确定入住ICU的危险因素,以及与ICU监护相关的疗效。 该试验回顾性分析了来自于单一医院2002年至2012年之间治疗的1279例髋部骨折的连续病例。患者平均年龄为83岁(范围:67-92岁)。比较入住ICU病例与未入住病例的人口统计

髋部骨折病例伴有明显的合并症发生率及死亡率。但到目前为止,尚缺乏对因为出现并发症而入住ICU监护治疗的髋部骨折病例的相关研究。本研究试图确定入住ICU的危险因素,以及与ICU监护相关的疗效。

该试验回顾性分析了来自于单一医院2002年至2012年之间治疗的1279例髋部骨折的连续病例。患者平均年龄为83岁(范围:67-92岁)。比较入住ICU病例与未入住病例的人口统计学参数、围手术期并发症以及住院期间死亡率之间的差异。重点关注ICU监护治疗期间升压药的使用情况。

试验中总共有470例患者术后需要入住ICU监护治疗,占所有髋部骨折病例的36.7%.ICU治疗组中45例(9.4%)患者因顽固性低血压予以升压药治疗。约93%的接受升压药治疗的病例在末次随访之前死亡。术后30天、90天和1年的死亡率分别为36%、49%和60%.入住ICU但无需升压药治疗的病例末次随访时的死亡率为68%,其中术后30天的死亡率为9.6%.术后未入住ICU的病例在末次随访时的死亡率为46.6%.接受升压药和未接受升压药的病例在年龄、性别、美国麻醉医师协会(ASA)分级、骨折治疗方式、医师类别以及手术时间之间均无显著差异。接受升压药治疗病例的住院时间显著长于未接受者(p<0.00001)。

髋部骨折术后需要入住ICU监护治疗预示着生存率较差。本组总共有36.7%的髋部骨折病例需要入住ICU,而其中接受升压药治疗病例在末次随访时的死亡率高达93%.术前采用一定的措施使这一类病情严重的患者身体状况达到最佳状态再接受手术治疗极为重要。

原始出处:

Diren Arsoy, Atul F. Kamath, Joseph R. Cass, Arun Subramanian,Stephen A. Sems, Robert T. Trousdale.ICU Admission and Vasopressor Support Results in Poor Survivorship after Hip Fracture Surgery.AAOS Mar 12, 2014

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2071203, encodeId=aa5320e12038a, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Aug 16 18:22:00 CST 2014, time=2014-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642882, encodeId=30b716428826a, content=<a href='/topic/show?id=1e19168181' target=_blank style='color:#2F92EE;'>#AAOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1681, encryptionId=1e19168181, topicName=AAOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c11e23034343, createdName=ms1260584454294838, createdTime=Wed Jan 14 15:22:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256483, encodeId=9e70125648340, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Mar 29 00:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408457, encodeId=cd4e140845e8c, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Sat Mar 29 00:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=)]
    2014-08-16 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2071203, encodeId=aa5320e12038a, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Aug 16 18:22:00 CST 2014, time=2014-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642882, encodeId=30b716428826a, content=<a href='/topic/show?id=1e19168181' target=_blank style='color:#2F92EE;'>#AAOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1681, encryptionId=1e19168181, topicName=AAOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c11e23034343, createdName=ms1260584454294838, createdTime=Wed Jan 14 15:22:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256483, encodeId=9e70125648340, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Mar 29 00:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408457, encodeId=cd4e140845e8c, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Sat Mar 29 00:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2071203, encodeId=aa5320e12038a, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Aug 16 18:22:00 CST 2014, time=2014-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642882, encodeId=30b716428826a, content=<a href='/topic/show?id=1e19168181' target=_blank style='color:#2F92EE;'>#AAOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1681, encryptionId=1e19168181, topicName=AAOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c11e23034343, createdName=ms1260584454294838, createdTime=Wed Jan 14 15:22:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256483, encodeId=9e70125648340, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Mar 29 00:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408457, encodeId=cd4e140845e8c, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Sat Mar 29 00:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2071203, encodeId=aa5320e12038a, content=<a href='/topic/show?id=ab241680a3' target=_blank style='color:#2F92EE;'>#AAO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1680, encryptionId=ab241680a3, topicName=AAO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Aug 16 18:22:00 CST 2014, time=2014-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642882, encodeId=30b716428826a, content=<a href='/topic/show?id=1e19168181' target=_blank style='color:#2F92EE;'>#AAOS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1681, encryptionId=1e19168181, topicName=AAOS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c11e23034343, createdName=ms1260584454294838, createdTime=Wed Jan 14 15:22:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256483, encodeId=9e70125648340, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat Mar 29 00:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408457, encodeId=cd4e140845e8c, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Sat Mar 29 00:22:00 CST 2014, time=2014-03-29, status=1, ipAttribution=)]
    2014-03-29 liuquan

相关资讯

AAOS:抗骨质疏松治疗可降低髋部骨折老年女性的死亡风险

引言:尽管人们已非常清楚髋部骨折术后早期有较高死亡率的风险,但目前尚无充分证据表明抗骨质疏松治疗是否有助于降低术后死亡率。本研究旨在探讨老年女性患者发生髋部骨折后予以抗骨质疏松治疗与死亡率之间的关系。方法:我们设计了一项回顾性非盲随机对照研究,以确定老年女性患者因髋部骨折接受手术治疗后接受抗骨质疏松治疗是否有助于降低术后2年的死亡率。总共有255例55岁以上,因低能量损伤导致首次髋部骨折的女性患者

在起始降压药治疗的头45天内高血压老年患者髋部骨折危险增加

加拿大一项以人群为基础的自我对照系列病例研究显示,在社区老年患者开始降压治疗的过程中,起始使用降压药与髋部骨折危险即刻增加相关。11月19日论文在线发表于《内科学文献》(Arch Intern Med)杂志。研究者将危险期定义为开始降压治疗后的头45天,将对照期定义为在观察期(每例患者为450天)中,除危险期外的低风险(高风险期过后的连续135天)和尚未使用药物(治疗之前的连续135天)的部分时间

AAOS 2014:氯吡格雷对髋部骨折治疗出血风险无增加

背景:目前,髋部骨折的发生越来越多,同时接受氯吡格雷治疗的病例也越来越多。早期处理髋部骨折会明显降低围手术期合并症的发生率。尽管要求在髋部骨折术前停止氯吡格雷的使用,但其抗血小板效果会继续保持5-7天,从而有增加早期手术干预围手术期出血的潜在风险。目前很少有针对非择期骨科手术围手术期氯吡格雷用法的指南。本研究旨在回顾性分析本院对接受氯吡格雷治疗的髋部骨折病例的处置方案(对手术时间的推迟),及其